Abstract The Argus® II Retinal Prosthesis System (Second Sight Medical Products) is the
first prosthetic vision device to obtain regulatory approval in both Europe and the USA. As …

Retinitis pigmentosa (RP) is genetically heterogeneous retinopathy caused by
photoreceptor cell death and retinal pigment epithelial atrophy that eventually results in …

Inherited retinal dystrophies and late-stage age-related macular degeneration, for which
treatments remain limited, are among the most prevalent causes of legal blindness. Retinal …

As solid‐state light sources based on amorphous organic semiconductors, organic light‐
emitting diodes (OLEDs) are widely used in modern smartphone displays and TVs. Due to …

Gene therapy is an evolving field in medicine and ophthalmology. Its success and
application depends on several factors that are specific to the disease to treat. For now, we …

The human retina fails to regenerate and cell-based therapies offer options for treatment of
blinding retinal diseases, such as macular degeneration and retinitis pigmentosa. The last …

In 2001, the first large animal was successfully treated with a gene therapy that restored its
vision. Lancelot, the Briard dog that was treated, suffered from a human childhood blindness …

Leber congenital amaurosis (LCA) is a severe congenital/early-onset retinal dystrophy.
Given its monogenic nature and the immunological and anatomical privileges of the eye …

Near‐infrared (NIR) activatable upconversion nanoparticles (UCNPs) enable wireless‐
based phototherapies by converting deep‐tissue‐penetrating NIR to visible light. UCNPs …

Gene therapy has emerged as a research topic of choice in recent years. The eye in
particular is one of few organs of the body for which gene therapy has received Food and …